
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The authors offer the primary care pediatrician a framework for thoughtful and directed use of the ever-increasing number of diagnostic tests available to assess developmental delays.






